These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38777970)

  • 1. Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.
    Niu C; Zhang J; Napel M; Boppana LKT; Anas H; Jadhav N; Dunnigan K; Okolo PI
    Clin Drug Investig; 2024 Jun; 44(6):371-385. PubMed ID: 38777970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
    Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
    J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
    Friedberg S; Choi D; Hunold T; Choi NK; Garcia NM; Picker EA; Cohen NA; Cohen RD; Dalal SR; Pekow J; Sakuraba A; Krugliak Cleveland N; Rubin DT
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1913-1923.e2. PubMed ID: 36898598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.
    Traboulsi C; Ayoub F; Silfen A; Rodriguez TG; Rubin DT
    Dig Dis Sci; 2023 Feb; 68(2):385-388. PubMed ID: 35695972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study.
    Zhang J; Li R; Chen L; Wang F; Zhou H; Liu X; Fan Z; Shi Y; Wu T; Wu K; Liang J
    Clin Exp Med; 2024 Sep; 24(1):233. PubMed ID: 39348049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
    Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies.
    Zheng DY; Wang YN; Huang YH; Jiang M; Dai C
    Int Immunopharmacol; 2024 Jan; 126():111229. PubMed ID: 37977068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
    Chugh R; Braga-Neto MB; Fredrick TW; Ramos GP; Terdiman J; El-Nachef N; Loftus EV; Mahadevan U; Kane SV
    J Crohns Colitis; 2023 Apr; 17(4):504-512. PubMed ID: 36272109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
    Mysler E; Burmester GR; Saffore CD; Liu J; Wegrzyn L; Yang C; Betts KA; Wang Y; Irvine AD; Panaccione R
    Adv Ther; 2024 Feb; 41(2):567-597. PubMed ID: 38169057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    Raine T; Ishiguro Y; Rubin DT; Finney-Hayward T; Vladea R; Liu J; Phillips C; Cheng E; Targownik L; Loftus EV
    J Crohns Colitis; 2024 May; 18(5):695-707. PubMed ID: 37942921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib in Crohn's disease.
    Dignass A; Esters P; Flauaus C
    Expert Opin Pharmacother; 2024 Mar; 25(4):359-370. PubMed ID: 38512115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lasa JS; Olivera PA; Danese S; Peyrin-Biroulet L
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):161-170. PubMed ID: 34856198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
    Loftus EV; Panés J; Lacerda AP; Peyrin-Biroulet L; D'Haens G; Panaccione R; Reinisch W; Louis E; Chen M; Nakase H; Begun J; Boland BS; Phillips C; Mohamed MF; Liu J; Geng Z; Feng T; Dubcenco E; Colombel JF
    N Engl J Med; 2023 May; 388(21):1966-1980. PubMed ID: 37224198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.
    Odah T; Karime C; Desai A; Picco MF; Kinnucan JA; Hashash JG; Farraye FA
    Dig Dis Sci; 2024 Oct; 69(10):3911-3919. PubMed ID: 39251560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.